ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)

被引：0
|
作者：
B Selle
C Bär
S Hecker
U Schmidt-Rohr
S Viehmann
K-M Debatin
D Reinhardt
机构：
[1] University of Heidelberg,Department of Pediatric Oncology and Hematology
[2] University of Giessen,Department of Pediatric Oncology and Hematology
[3] University of Ulm,Department of Pediatric Oncology and Hematology
[4] University of Münster,Department of Pediatric Oncology and Hematology
来源：
Leukemia | 2002年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1393 / 1395
页数：2
相关论文
共 50 条
  • [1] ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)
    Selle, B
    Bär, C
    Hecker, S
    Schmidt-Rohr, U
    Viehmann, S
    Debatin, KM
    Reinhardt, D
    LEUKEMIA, 2002, 16 (07) : 1393 - 1395
  • [2] Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era
    Shimizu, Hiroaki
    Yokohama, Akihiko
    Hatsumi, Nahoko
    Takada, Satoru
    Handa, Hiroshi
    Sakura, Toru
    Nojima, Yoshihisa
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (04) : 297 - 301
  • [3] Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia
    Akahoshi, Yu
    Nishiwaki, Satoshi
    Mizuta, Shuichi
    Ohashi, Kazuteru
    Uchida, Naoyuki
    Tanaka, Masatsugu
    Fukuda, Takahiro
    Ozawa, Yukiyasu
    Takahashi, Satoshi
    Onizuka, Makoto
    Shiratori, Souichi
    Nakamae, Hirohisa
    Kanda, Yoshinobu
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Kako, Shinichi
    CANCER SCIENCE, 2019, 110 (10) : 3255 - 3266
  • [4] The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Maekawa, Taira
    Ashihara, Eishi
    Kimura, Shinya
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 327 - 340
  • [5] The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Taira Maekawa
    Eishi Ashihara
    Shinya Kimura
    International Journal of Clinical Oncology, 2007, 12 : 327 - 340
  • [6] Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Steinberg, Michael
    CLINICAL THERAPEUTICS, 2007, 29 (11) : 2289 - 2308
  • [7] The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia
    Wu, Xiaoxia
    Lu, Shenqi
    Zhang, Xinhui
    Yang, Zhen
    Sun, Aining
    Wu, Depei
    Zhou, Huifen
    Miao, Miao
    CANCER MEDICINE, 2024, 13 (17):
  • [8] Ponatinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Shamroe, Caitlin L.
    Comeau, Jill M.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1540 - 1546
  • [9] The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment
    Thomas, Xavier
    Heiblig, Mael
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (11) : 1061 - 1070
  • [10] Managing Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitors
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (02): : 198 - 203
12345